✦ LIBER ✦
2135 POSTER Cost-effectiveness (CE) of lapatinib plus capecitabine (L+C) in women with ErbB2+ (HER2+) metastatic breast cancer (MBC) who have received prior therapy with trastuzumab (TZ) from the United Kingdom (UK) National Health Service (NHS) perspective
✍ Scribed by T.E. Delea; P. Tappenden; O. Sofrygin; J. Karnon; M. Amonkar; D. Browning; H. Rudge; M. Walker
- Book ID
- 118625739
- Publisher
- Elsevier Science
- Year
- 2007
- Tongue
- English
- Weight
- 64 KB
- Volume
- 5
- Category
- Article
- ISSN
- 1359-6349
No coin nor oath required. For personal study only.